A study published in the Journal of Experimental & Clinical Cancer Research finds that tumor-bearing lymph node-specific CTLA4 blockade effectively limits lymph node metastasis and prevents systemic metastasis, thereby prolonging survival.
]. Thus, MXH10/Mo/lpr is a suitable model to study to the consequences of immune checkpoint blockade and is critical to the understanding of ICI-induced irAEs, which in turn can inform the design of personalized therapeutics to ameliorate ICI-induced irAEs or uncouple them from the therapeutic response.
LM8-Luc cells in a 1:2 mixture of PBS and Matrigel , were unilaterally or bilaterally inoculated to the center of the SiLN of MXH10/Mo/lpr mice to establish murine models to facilitate study of metastatic LNs. Skin was depilated and an incision was made prior to inoculation to expose the SiLN.
Subsequently, to determine the sensitivity of therapeutic response to anti-CTLA4 dosage, a dose de-escalation study was performed. On day 4, 1 mg/kg or 5 mg/kg anti-CTLA4 mAb was administered to the tbLN through LDDS of unilaterally inoculated mice.